SAN FRANCISCO — Aimmune Therapeutics CEO Jayson Dallas would be enjoying his time at the J.P. Morgan Healthcare Conference a lot more this week if the U.S. government were open for business. Instead, in between meetings with investors and other health care folks, Dallas is being forced to monitor D.C. gridlock because his company’s experimental treatment to protect people against peanut allergy is in FDA limbo.

“It’s frustrating,” Dallas said in an interview Tuesday during JPM Week.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • There is an upside then

    stopping biomedical scams from being validated. Unfortunate, in reality, it is just a slow down

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy